Research Methods Core: Cognitive Neuroscience

研究方法核心:认知神经科学

基本信息

项目摘要

The revolutionary growth of the cognitive neurosciences offers enormous promise for understanding the mechanisms underlying antipsychotic interventions. The overarching goal of the Research Methods Core is to support the application of state-of-the-art neurocognitive and neuroimaging methodologies that may help clarify the mechanisms underlying effective intervention in schizophrenia such as the prediction of treatment response, functional outcome, and adverse events in a unique cohort of first episode patients with minimal or no prior antipsychotic drug exposure. Compared to conventional treatment targets such as clinical symptomatology, cognitive neuroscience methods theoretically are more closely representative of brain dysfunction, and should ultimately be superior: (1) in classifying individuals who will benefit differentially from specific treatments, and some day, in the selection, dosing and titration of treatments; (2) in identifying the stable, enduring features of pathology that are most likely to predict distinctive outcomes, with implications for disposition and rehabilitative efforts; (3) in identifying neurobiological mechanisms that mediate treatment response with current, second-generation antipsychotics; and finally, (4) in serving as treatment targets themselves, possibly leading to the next generation of rationally-derived treatments. Moreover, information derived from cognitive neuroscience methods in well-controlled clinical trials will further provide crucial feedback to basic neuroscience research about the mechanisms underlying effective treatment. The Research Methods Core provides infrastructure support for the individual research projects, which include assessment of neurocognitive functioning, region-of-interest volumetric approaches, diffusion tensor imaging, cortical surface mapping and positron emission tomography to predict treatment response and multidimensional outcome measures. The specific aims of the Core include: (1) to integrate individual projects within the Center; (2) to develop innovative methods for data analysis and image processing; (3) to communicate findings and train investigators in neuropsychological and neuroimaging methods and (4) to maintain high standards of reliability for individual research projects. Mechanisms by which the Core accomplishes these aims will be addressed in turn, after a brief overview of the three major platforms for cognitive neuroscience research within the ZHH CIDAR.
认知神经科学的革命性发展为理解神经系统疾病提供了巨大的希望

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Terry Goldberg其他文献

Terry Goldberg的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Terry Goldberg', 18)}}的其他基金

Cognitive Assessment and Adjudication Core
认知评估与判定核心
  • 批准号:
    10507631
  • 财政年份:
    2022
  • 资助金额:
    $ 25.84万
  • 项目类别:
Novel Cognitive and Functional Measure for Alzheimer's Disease Prevention Trials
阿尔茨海默病预防试验的新认知和功能测量
  • 批准号:
    10179171
  • 财政年份:
    2018
  • 资助金额:
    $ 25.84万
  • 项目类别:
Novel Cognitive and Functional Measure for Alzheimer's Disease Prevention Trials
阿尔茨海默病预防试验的新认知和功能测量
  • 批准号:
    10202448
  • 财政年份:
    2018
  • 资助金额:
    $ 25.84万
  • 项目类别:
Novel Cognitive and Functional Measure for Alzheimer's Disease Prevention Trials
阿尔茨海默病预防试验的新认知和功能测量
  • 批准号:
    10440277
  • 财政年份:
    2018
  • 资助金额:
    $ 25.84万
  • 项目类别:
Novel Cognitive and Functional Measure for Alzheimer's Disease Prevention Trials
阿尔茨海默病预防试验的新认知和功能测量
  • 批准号:
    9763392
  • 财政年份:
    2018
  • 资助金额:
    $ 25.84万
  • 项目类别:
BDNF val66met Genotype and Age: Hurricane Sandy Supplement
BDNF val66met 基因型和年龄:飓风桑迪补充剂
  • 批准号:
    8744534
  • 财政年份:
    2013
  • 资助金额:
    $ 25.84万
  • 项目类别:
BDNF val66met Genotype and Age: Impact on Biomarkers and Exercise-based Treatment
BDNF val66met 基因型和年龄:对生物标志物和运动治疗的影响
  • 批准号:
    8523730
  • 财政年份:
    2011
  • 资助金额:
    $ 25.84万
  • 项目类别:
BDNF val66met Genotype and Age: Impact on Biomarkers and Exercise-based Treatment
BDNF val66met 基因型和年龄:对生物标志物和运动治疗的影响
  • 批准号:
    8852512
  • 财政年份:
    2011
  • 资助金额:
    $ 25.84万
  • 项目类别:
BDNF val66met Genotype and Age: Impact on Biomarkers and Exercise-based Treatment
BDNF val66met 基因型和年龄:对生物标志物和运动治疗的影响
  • 批准号:
    8187331
  • 财政年份:
    2011
  • 资助金额:
    $ 25.84万
  • 项目类别:
BDNF val66met Genotype and Age: Impact on Biomarkers and Exercise-based Treatment
BDNF val66met 基因型和年龄:对生物标志物和运动治疗的影响
  • 批准号:
    8328894
  • 财政年份:
    2011
  • 资助金额:
    $ 25.84万
  • 项目类别:

相似海外基金

Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
  • 批准号:
    10707830
  • 财政年份:
    2023
  • 资助金额:
    $ 25.84万
  • 项目类别:
Hospital characteristics and Adverse event Rate Measurements (HARM) Evaluated over 21 years.
医院特征和不良事件发生率测量 (HARM) 经过 21 年的评估。
  • 批准号:
    479728
  • 财政年份:
    2023
  • 资助金额:
    $ 25.84万
  • 项目类别:
    Operating Grants
Analysis of ECOG-ACRIN adverse event data to optimize strategies for the longitudinal assessment of tolerability in the context of evolving cancer treatment paradigms (EVOLV)
分析 ECOG-ACRIN 不良事件数据,以优化在不断发展的癌症治疗范式 (EVOLV) 背景下纵向耐受性评估的策略
  • 批准号:
    10884567
  • 财政年份:
    2023
  • 资助金额:
    $ 25.84万
  • 项目类别:
AE2Vec: Medical concept embedding and time-series analysis for automated adverse event detection
AE2Vec:用于自动不良事件检测的医学概念嵌入和时间序列分析
  • 批准号:
    10751964
  • 财政年份:
    2023
  • 资助金额:
    $ 25.84万
  • 项目类别:
Understanding the real-world adverse event risks of novel biosimilar drugs
了解新型生物仿制药的现实不良事件风险
  • 批准号:
    486321
  • 财政年份:
    2022
  • 资助金额:
    $ 25.84万
  • 项目类别:
    Studentship Programs
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
  • 批准号:
    10676786
  • 财政年份:
    2022
  • 资助金额:
    $ 25.84万
  • 项目类别:
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
  • 批准号:
    10440970
  • 财政年份:
    2022
  • 资助金额:
    $ 25.84万
  • 项目类别:
Improving Adverse Event Reporting on Cooperative Oncology Group Trials
改进肿瘤学合作组试验的不良事件报告
  • 批准号:
    10642998
  • 财政年份:
    2022
  • 资助金额:
    $ 25.84万
  • 项目类别:
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
  • 批准号:
    10482465
  • 财政年份:
    2022
  • 资助金额:
    $ 25.84万
  • 项目类别:
Expanding and Scaling Two-way Texting to Reduce Unnecessary Follow-Up and Improve Adverse Event Identification Among Voluntary Medical Male Circumcision Clients in the Republic of South Africa
扩大和扩大双向短信,以减少南非共和国自愿医疗男性包皮环切术客户中不必要的后续行动并改善不良事件识别
  • 批准号:
    10191053
  • 财政年份:
    2020
  • 资助金额:
    $ 25.84万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了